Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prosturol is a medical device developed by Apogepha Arzneimittel GmbH for the symptomatic treatment of conditions affecting the prostate and anorectal canal. It is formulated as a rectal suppository containing a complex combination of plant-based ingredients, including pumpkin seeds, Indian pennywort (*Centella asiatica*), frankincense, straw flower, and Australian tea tree, along with vitamin E acetate and hyaluronic acid sodium salt. Prosturol is indicated for the soothing and softening local treatment of the anorectal canal in congestive conditions associated with acute and chronic prostatitis as well as benign prostatic hyperplasia (BPH). Its mechanism of action is primarily physical and mechanical, utilizing tissue-relaxing properties supported by its botanical and hydrating components to provide relief from local congestion and discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prosturol.